HC Wainwright Has Bullish Outlook for ZVRA FY2027 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at HC Wainwright raised their FY2027 EPS estimates for shares of Zevra Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.55 per share for the year, up from their prior forecast of $0.46. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2028 earnings at $0.61 EPS, FY2029 earnings at $1.13 EPS and FY2030 earnings at $1.69 EPS.

A number of other brokerages have also issued reports on ZVRA. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Thursday, August 6th. Cantor Fitzgerald increased their price target on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. UBS Group reissued a “buy” rating on shares of Zevra Therapeutics in a report on Wednesday, June 24th. BTIG Research decreased their target price on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Monday, July 27th. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.14.

Zevra Therapeutics Stock Down 1.2%

ZVRA stock opened at $11.34 on Monday. The stock’s 50 day moving average is $12.33 and its two-hundred day moving average is $10.62. Zevra Therapeutics has a 52-week low of $7.16 and a 52-week high of $15.03. The company has a market capitalization of $673.37 million, a PE ratio of 12.33 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The business had revenue of $39.66 million for the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ZVRA. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in Zevra Therapeutics during the 4th quarter valued at about $53,000. Russell Investments Group Ltd. boosted its stake in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after buying an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after acquiring an additional 8,552 shares in the last quarter. Creative Planning acquired a new position in shares of Zevra Therapeutics in the 2nd quarter worth approximately $92,000. Finally, Quarry LP bought a new stake in Zevra Therapeutics during the third quarter worth approximately $103,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.